Published: Sat, January 13, 2018
Finance | By Loren Pratt

Vicus Capital Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)


The hedge fund run by Israel Englander held 279,772 shares of the health care company at the end of 2017Q3, valued at $22.67M, down from 3.00 million at the end of the previous reported quarter. Harvey Capital Management Inc who had been investing in Gilead Sciences for a number of months, seems to be less bullish one the $103.17 billion market cap company. The lowest price the stock reached in the last trading day was $7.7137 and compares with the $6.71 52-week low. Another trade for 25,000 shares valued at $2.07M was made by Alton Gregg H on Monday, October 2.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. It has underperformed by 38.50% the S&P500. (NASDAQ:TRUE) rating on Friday, July 24. Therefore 50% are positive. The lowest target is $7200 while the high is $137. The first line is called the %K line, which analyzes the actual price movements in the shares and can be defined as: %K = (Current Close - Lowest Low)/(Highest High - Lowest Low) * 100. Gilead Sciences's dividend payout ratio is 23.66%. The firm has "Buy" rating by Cowen & Co given on Monday, September 21. Aegis Capital maintained it with "Buy" rating and $117100 target in Friday, July 28 report. (NASDAQ:SUPN) rating on Tuesday, September 19. The rating was upgraded by Maxim Group to "Buy" on Thursday, November 30. The firm has "Neutral" rating given on Friday, January 15 by Bank of America. The firm earned "Buy" rating on Tuesday, July 25 by Piper Jaffray. (NASDAQ:GILD) earned "Hold" rating by BMO Capital Markets on Monday, August 28. On Wednesday, October 4 the stock rating was maintained by Jefferies with "Hold". They issued an "outperform" rating and a $94.00 price target for the company. Goldman Sachs downgraded TrueCar, Inc. The stock has "Hold" rating by Jefferies on Wednesday, September 9. On Wednesday, August 30 the insider COURTOIS JEAN PHILIPPE sold $1.98M. (NASDAQ:GILD) higher to the next line of resistance at $80.68 a share. Morfit G Mason sold $507.89 million worth of stock. The companyÂ's Productivity and Business Processes segment offers Office 365 commercial services and products for businesses, including Office, Exchange, SharePoint, Skype for Business, and related Client Access Licenses; Office 365 consumer services, such as Skype, Outlook.com, and OneDrive; Dynamics business solutions, such as financial management, enterprise resource planning, customer relationship management, supply chain management, and analytics applications for small and mid-size businesses, large organizations, and divisions of enterprises; and LinkedIn online professional network. It has a 9 P/E ratio.

Several analysts have recently issued reports on the company. (NYSE:GTN). Envestnet Asset invested 0% of its portfolio in Gray Television, Inc. Its up 0.10, from 0.93 in 2017Q2. 114 funds opened positions while 708 raised stakes. Clarivest Asset Ltd Llc reported 3,567 shares stake. Blackrock has 0% invested in Gray Television, Inc. Calamos Wealth Ltd Liability Corp has invested 0.83% in Lam Research Corporation (NASDAQ:LRCX). Ct Mason holds 129,558 shares or 3.51% of its portfolio. Moreover, Cortina Asset Ltd Limited Liability Company has 0.15% invested in Supernus Pharmaceuticals, Inc. Vaughan Nelson Mngmt L P reported 1.08% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Zpr Investment Management who had been investing in Tower Intl Inc for a number of months, seems to be less bullish one the $650.75M market cap company. Palestra Capital Limited Liability Company stated it has 1.14M shares. 99,605 are owned by Hall Laurie J Trustee.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on January, 24. For the last quarter, the company's quarterly EPS was -$0.01. GILD's profit will be $2.18 billion for 11.87 P/E if the $1.67 EPS becomes a reality.


Tracking other technical indicators, the 14-day RSI is presently standing at 68.36, the 7-day sits at 80.27, and the 3-day is resting at 93.79 for Gilead Sciences Inc (GILD). The stock decreased 0.26% or $0.03 during the last trading session, reaching $11.65. About 871,356 shares traded. Pain Therapeutics, Inc. (NASDAQ:PTIE) has declined 72.83% since January 12, 2017 and is downtrending. It has outperformed by 18.44% the S&P500.

Since August 1, 2017, it had 0 insider buys, and 11 sales for $41.13 million activity. If Gilead Sciences, Inc. Shares for $3.68 million were sold by MARTIN JOHN C. Over the last 90 days, insiders sold 461,666 shares of company stock worth $34,072,567.

Investors sentiment decreased to 1.17 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It improved, as 96 investors sold GILD shares while 488 reduced holdings. Westwood Group holds 0.41% or 280,633 shares. Fulton Breakefield Broenniman Limited Com owns 1.13% invested in Gilead Sciences, Inc. In that case, its shares would mark a 0.93% decline from the most recent price. The Massachusetts-based North Tide Capital Llc has invested 8.64% in the stock. Traynor Capital Management Inc. now owns 20,375 shares of the biopharmaceutical company's stock worth $1,709,000 after buying an additional 1,357 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Gilead Sciences by 0.7% in the second quarter. Foster And Motley Inc, Ohio-based fund reported 8,579 shares. Meiji Yasuda Life Ins owns 14,565 shares for 0.4% of their portfolio. United Services Automobile Association reported 75,580 shares. Public Employees Retirement Association Of Colorado has invested 0.43% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Point72 Asia (Hong Kong) Ltd holds 0.17% or 2,981 shares. 32,673 were reported by Hemenway Comm Limited Co. (NASDAQ:GILD). Linscomb Williams Inc holds 0.04% or 6,046 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Like this: